
    
      Head and neck cancer / Esophageal squamous cancer patients who have disease progression after
      first standard regimen will be treated by metronomic Capecitabine plus Camrelizumab.
      Metronomic Capecitabine will be given as fixed dose (500mg bid) orally. Camrelizumab will be
      given two-weekly (200mg once) intravenously. This regimen will be administered until
      progression of disease, intolerable toxicity or withdraw of consent.
    
  